Mostrando 10 resultados de: 235
Publisher
Pharmacogenomics(32)
Pharmacogenomics Journal(23)
Drug Metabolism and Personalized Therapy(14)
Drug Metabolism and Drug Interactions(12)
European Journal of Clinical Pharmacology(11)
Área temáticas
Farmacología y terapéutica(151)
Enfermedades(105)
Medicina y salud(56)
Bioquímica(48)
Fisiología humana(37)
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
ArticleAbstract: To investigate the importance of genetic factors for the regulation of haloperidol metabolism, we stPalabras claves:debrisoquine, Haloperidol, humans, pharmacogeneticsAutores:Adrián LLerena, Alm C., Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
ArticleAbstract: We have previously shown that the disposition of haloperidol is decreased in poor (PM) compared to ePalabras claves:debrisoquine, humans, pharmacogenetics, Reduced haloperidolAutores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHepatic actinomycosis
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Jiménez M., Muñoz Sanz A., Sáenz de Santamaría J.Fuentes:scopusHigh frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopusHigh frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
ArticleAbstract: A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was repPalabras claves:Autores:Adrián LLerena, Dorado P., Ferreiro V., Moya G.E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusHigh prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
ArticleAbstract: Background: Interethnic differences in CYP2D6 allele frequency have been demonstrated across Latin-APalabras claves:COLOMBIA, CYP2D6, Hispanics, Mestizos, Ultrarapid metabolizersAutores:Adrián LLerena, Borbón-Orejuela A., de Andrés F., Dorado P., P Sarmiento A.Fuentes:scopusHigh risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopusHigh risk of polydipsia and water intoxication in schizophrenia patients
OtherAbstract:Palabras claves:Autores:Adrián LLerena, De la Rubia A., González I., Penãs-Lledó E.M., Pérez N.Fuentes:scopusHigh-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
ArticleAbstract: Background: Aripiprazole (ARI) is an antipsychotic drug that is metabolized to dehydroaripiprazole (Palabras claves:Aripiprazole, CYP2D6, Dehydroaripiprazole, High-performance liquid chromatography, Psychiatric patientsAutores:Adrián LLerena, de Andrés F., De la Rubia A., Dorado P., Gonz Ález A., Gonz Ález I., Naranjo M.E.G., Peñ As-Lledó E.Fuentes:scopus